Biotech IPOs have slept through 2023. When will they wake up?


The biotech IPO market has ground to a halt. Experts believe the window may open again in the next year. Here are the signs they're looking for.

Previous Biotech layoffs 2023: In Q2, more than 700 Boston-area life science jobs were cut
Next Rich Products' 'lift-and-adapt' strategy fuels ongoing global growth at the $5.8B business